Atossa Therapeutics 향후 성장

Future 기준 점검 3/6

Atossa Therapeutics은 연간 수입과 매출이 각각 62%와 62.4% 증가할 것으로 예상되고 EPS는 연간 63.1%만큼 증가할 것으로 예상됩니다.

핵심 정보

62.0%

이익 성장률

63.09%

EPS 성장률

Biotechs 이익 성장	25.4%
매출 성장률	62.4%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	13 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • Dec 03

Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

분석 기사 • Jul 15

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

분석 기사 • Apr 01

Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

분석 기사 • Nov 12

Atossa Therapeutics (NASDAQ:ATOS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

분석 기사 • Nov 08

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

분석 기사 • Apr 26

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

분석 기사 • Jan 09

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

이익 및 매출 성장 예측

NasdaqCM:ATOS - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2028	81	8	-86	N/A	3
12/31/2027	N/A	-44	-71	-36	4
12/31/2026	N/A	-38	-45	-36	4
3/31/2026	N/A	-38	-33	-33	N/A
12/31/2025	N/A	-35	-30	-30	N/A
9/30/2025	N/A	-30	-26	-26	N/A
6/30/2025	N/A	-29	-25	-25	N/A
3/31/2025	N/A	-26	-22	-22	N/A
12/31/2024	N/A	-26	-21	-21	N/A
9/30/2024	N/A	-27	-20	-20	N/A
6/30/2024	N/A	-26	-19	-19	N/A
3/31/2024	N/A	-30	-19	-19	N/A
12/31/2023	N/A	-30	-21	-21	N/A
9/30/2023	N/A	-30	-20	-20	N/A
6/30/2023	N/A	-32	-21	-21	N/A
3/31/2023	N/A	-28	-23	-23	N/A
12/31/2022	N/A	-27	-21	-21	N/A
9/30/2022	N/A	-24	-20	-20	N/A
6/30/2022	N/A	-21	-18	-18	N/A
3/31/2022	N/A	-22	-17	-17	N/A
12/31/2021	N/A	-21	-16	-16	N/A
9/30/2021	N/A	-28	-16	-16	N/A
6/30/2021	N/A	-26	-16	-16	N/A
3/31/2021	N/A	-23	-13	-13	N/A
12/31/2020	N/A	-22	-12	-12	N/A
9/30/2020	N/A	-13	-11	-11	N/A
6/30/2020	N/A	-13	-10	-10	N/A
3/31/2020	N/A	-16	-10	-10	N/A
12/31/2019	N/A	-17	N/A	-9	N/A
9/30/2019	N/A	-17	N/A	-9	N/A
6/30/2019	N/A	-17	N/A	-9	N/A
3/31/2019	N/A	-25	N/A	-9	N/A
12/31/2018	N/A	-23	N/A	-9	N/A
9/30/2018	N/A	-23	N/A	-8	N/A
6/30/2018	N/A	-22	N/A	-8	N/A
3/31/2018	N/A	-11	N/A	-7	N/A
12/31/2017	N/A	-11	N/A	-7	N/A
9/30/2017	N/A	-11	N/A	-6	N/A
6/30/2017	N/A	-9	N/A	-4	N/A
3/31/2017	N/A	-6	N/A	-4	N/A
12/31/2016	N/A	-6	N/A	-5	N/A
9/30/2016	0	-6	N/A	-8	N/A
6/30/2016	0	-10	N/A	-12	N/A
3/31/2016	0	-12	N/A	-14	N/A
12/31/2015	0	-13	N/A	-14	N/A
9/30/2015	0	-13	N/A	-13	N/A
6/30/2015	0	-13	N/A	-12	N/A

애널리스트 향후 성장 전망

수입 대 저축률: ATOS 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.5%)보다 빠른 성장으로 간주됩니다.

수익 vs 시장: ATOS (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: ATOS 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: ATOS 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 매출: ATOS 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: ATOS의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/22 23:03
종가	2026/05/22 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Atossa Therapeutics, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Edward Woo	Ascendiant Capital Markets LLC
Pooya Hemami	Edison Investment Research
Emily Bodnar	H.C. Wainwright & Co.

Atossa Therapeutics 향후 성장

Future 기준 점검 3/6

핵심 정보

최근 향후 성장 업데이트

Forecast to breakeven in 2028

No longer forecast to breakeven

Forecast to breakeven in 2028

Price target decreased by 7.3% to US$63.75

Price target increased by 10% to US$88.33

Price target decreased by 7.2% to US$80.00

Recent updates

Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For McCune-Albright Syndrome

Forecast to breakeven in 2028

No longer forecast to breakeven

New minor risk - Profitability

Atossa Therapeutics, Inc., Annual General Meeting, May 07, 2026

Atossa Therapeutics, Inc. Appoints Kathy Puyana Theall, M.D. as Medical Director - Breast Oncology and Adebola Giwa, M.D. as Medical Director - Rare Diseases

Atossa Therapeutics, Inc. Presents Clinical Trial Update On Z-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Forecast to breakeven in 2028

Price target decreased by 7.3% to US$63.75

New minor risk - Profitability

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Atossa Therapeutics, Inc. Regains Compliance with the Minimum Closing Bid Price Requirements

Price target increased by 10% to US$88.33

Price target decreased by 7.2% to US$80.00

New minor risk - Share price stability

Atossa Therapeutics, Inc. Receives FDA " Study May Proceed" Letter for (Z-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Forecast to breakeven in 2028

Atossa Therapeutics, Inc. Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research At the 2025 San Antonio Breast Cancer Symposium

Atossa Therapeutics, Inc. Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z-Endoxifen Across Breast Cancer Continuum

Is Atossa Therapeutics (NASDAQ:ATOS) In A Good Position To Invest In Growth?

New minor risk - Market cap size

Atossa Therapeutics, Inc. Highlights Emerging Opportunity for (Z-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Atossa Therapeutics, Inc. Highlights Progress in RECAST™? DCIS Platform Trial at Early Detection Research Conference

Atossa Therapeutics, Inc. Appoints Mark Daniel as Chief Financial Officer

Atossa Therapeutics, Inc. Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Atossa Therapeutics Appoints Janet R. Rea, MSPH, as Senior Vice President, R&D

Atossa Therapeutics, Inc. Announces Regulatory Strategy Aimed At Accelerating Development of Low-Dose (Z-Endoxifen for Breast Cancer Risk Reduction

Atossa Therapeutics, Inc. Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement

New minor risk - Market cap size

Atossa Therapeutics, Inc. Announces Positive FDA Feedback, Advances Toward IND for (Z-Endoxifen Clinical Program in E+/HER2- Metastatic Breast Cancer

Companies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In Growth

Price target decreased by 7.5% to US$5.63

Price target decreased by 7.3% to US$5.56

New minor risk - Market cap size

Atossa Therapeutics, Inc. Announces Full Results from I-SPY 2 Endocrine-Optimization Sub- Study Evaluating Low-Dose (Z)-Endoxifen

Atossa Therapeutics, Inc. Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation

Atossa Therapeutics, Inc., Annual General Meeting, May 08, 2025

New major risk - Revenue and earnings growth

Atossa Therapeutics, Inc. to Report Q4, 2024 Results on Mar 25, 2025

Atossa Therapeutics, Inc. Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Atossa Therapeutics, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New minor risk - Market cap size

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z-Endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Atossa Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Price target increased by 7.7% to US$5.83

New major risk - Revenue and earnings growth

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics: Important News, But The Company Still Has A Long Way To Go

Atossa Therapeutics Reports Positive Karisma-Endoxifen Trial Results

Atossa Therapeutics, Inc Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Atossa Therapeutics Grants Additional Patent Protection for Endoxifen

Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Forecast to breakeven in 2026

Atossa Therapeutics Completes Enrollment of 80Mg Pharmacokinetic Run-In Cohort in Phase 2 Evangeline Clinical Trial Evaluating (Z)-Endoxifen as A Neoadjuvant Treatment for Er+ / Her2- Breast Cancer

Atossa Therapeutics, Inc. Appoints Heather Rees as Chief Financial Officer

We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

No longer forecast to breakeven

Atossa Therapeutics, Inc. Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

Atossa Therapeutics, Inc. Announces Last Patient, Last Dose in Its Phase 2 Karisma-Endoxifen Clinical Trial

No longer forecast to breakeven

Atossa Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer

Atossa Therapeutics, Inc. Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

New minor risk - Profitability